Ambetter Nevada Intrathecal Pump Coverage

Coverage Criteria for Implantable Intrathecal or Epidural Drug Delivery Systems

inv-01: Preliminary Trial — Medical Necessity

Preliminary epidural or intrathecal opioid trial is medically necessary when ALL of the following are met:

Preliminary trial — indications and prerequisites: Request is for either: (1) chronic intractable pain of malignant origin when: a) inadequate response to, or intolerable side effects from, noninvasive methods of pain control such as systemic opioids; b) life expectancy > three months; c) no evidence of epidural metastatic lesion(s) or tumor encroachment of the thecal sac by imaging; OR (2) chronic intractable pain of nonmalignant origin when: a) pathology for the pain has been identified; b) life expectancy > three months; c) failure or inability to tolerate conservative treatments (systemic pharmacotherapy, physical therapy, behavioral health, appropriate nonsurgical treatment); d) compliance with prior treatment attempts; e) a psychological evaluation confirms mental health is not a major contributor to chronic pain symptoms; f) further surgical intervention not indicated or likely effective; g) prior to the trial, systemic opioids have been weaned by at least 50%; h) opioid induced hyperalgesia has been ruled out as a possible cause of the chronic pain symptoms.

Preliminary trial — contraindications (none present): None of the following contraindications are present: known allergies to materials in the implant; active alcohol or drug abuse (including opioid addiction and intravenous drug abuse); diagnosis of dementia or psychosis; active systemic infection; active infection at the site of implantation.

inv-02: Permanent Implantation — Medical Necessity

Permanent implantation of a pump is medically necessary when ALL of the following are met (for malignant and nonmalignant indications as specified):

Permanent implantation — malignant origin: For chronic intractable malignant pain: the preliminary trial criteria are met and the trial provided ≥ 50% reduction in pain with minimal side effects; body size is sufficient to support the weight and bulk of the device; no other implanted programmable devices for which interaction may inadvertently change the prescription; no known allergy or hypersensitivity to the drug being used.

Permanent implantation — nonmalignant origin: For severe chronic nonmalignant pain: the preliminary trial criteria are met and the trial provided ≥ 50% reduction in pain and increase in function with minimal side effects; there is a plan in place to continue to wean systemic opioids; no active coagulopathy; body size is sufficient to support the weight and bulk of the device; no other implanted programmable devices for which interaction may inadvertently change the prescription; no known allergy or hypersensitivity to the drug being used; no evidence of increased intracranial pressure; no spinal anomalies that may complicate implantation and fixation of a catheter for drug delivery; continued active participation in behavioral health or psychological treatment modalities.

Permanent implantation — contraindications (none present): None of the following contraindications are present: known allergies to materials in the implant; active alcohol or drug abuse (including opioid addiction and intravenous drug abuse); diagnosis of dementia or psychosis; active systemic infection; active infection at the site of implantation.

Relative and absolute contraindications must be verified and documented prior to trial or implantation. Absolute contraindications include systemic infections, known allergies to materials in the implant, active intravenous drug abuse, diagnosis of dementia or psychosis, and active infection at the implantation site.

Relative contraindications that may preclude proceeding without additional evaluation include an underweight/atrophied patient (low BMI), ongoing anticoagulation that cannot be safely stopped, active bleeding, very high opioid tolerance, lack of adequate social or family support, and lack of reliable access to follow-up medical care.

Providers should document the absence of listed absolute contraindications and address any relative contraindications in the medical record before scheduling a trial infusion or permanent implantation to avoid denial of coverage.

Coverage decisions for preliminary trials and permanent implantation are guided by this clinical policy but remain subject to the member's benefit terms. Providers must confirm plan-level prior authorization and any applicable exclusions or limitations in the member's coverage documents prior to submitting requests.

Where applicable, state Medicaid provisions and Medicare NCDs/LCDs take precedence and may affect coverage determinations; discrepancies between this policy and governing law or coverage documents will be resolved according to those authorities.

Use of intrathecal drug delivery systems for nonmalignant (chronic) pain is considered controversial and is generally reserved as a last resort after exhaustive conservative and surgical options have failed or are not tolerated.

Because long-term comparative evidence of superiority over oral opioids is limited, permanent implantation for noncancer pain requires strict adherence to the policy criteria (including successful trial response, documentation of failed conservative therapies, psychological evaluation, and plans for opioid weaning) before coverage will be considered.

Procedure, Device, and Supply Codes

CPT codes — injections and catheter placement (partial list)CPT

62320	Injection(s), interlaminar epidural or subarachnoid, cervical or thoracic; without imaging guidance.
62321	Injection(s), interlaminar epidural or subarachnoid, cervical or thoracic; with imaging guidance (ie, fluoroscopy or CT).
62322	Injection(s), interlaminar epidural or subarachnoid, lumbar or sacral (caudal); without imaging guidance.
62323	Injection(s), interlaminar epidural or subarachnoid, lumbar or sacral (caudal); with imaging guidance (ie, fluoroscopy or CT).
62326	Injection(s), including indwelling catheter placement, continuous infusion or intermittent bolus, interlaminar epidural or subarachnoid, lumbar or sacral (caudal); without imaging guidance.
62327	Injection(s), including indwelling catheter placement, continuous infusion or intermittent bolus, interlaminar epidural or subarachnoid, lumbar or sacral (caudal); with imaging guidance (ie, fluoroscopy or CT).

CPT codes — implantation, device management, analysisCPT

62350	Implantation, revision or repositioning of tunneled intrathecal or epidural catheter; without laminectomy.
62351	Implantation, revision or repositioning of tunneled intrathecal or epidural catheter; with laminectomy.
62355	Removal of previously implanted intrathecal or epidural catheter.
62360	Implantation or replacement of device for intrathecal or epidural drug infusion; subcutaneous reservoir.
62361	Implantation or replacement of device for intrathecal or epidural drug infusion; nonprogrammable pump.
62362	Implantation or replacement of device for intrathecal or epidural drug infusion; programmable pump, including preparation of pump, with or without programming.
62365	Removal of subcutaneous reservoir or pump, previously implanted for intrathecal or epidural infusion.
62367	Electronic analysis of programmable, implanted pump; without reprogramming or refill.
62368	Electronic analysis of programmable, implanted pump; with reprogramming.
62369	Electronic analysis of programmable, implanted pump; with reprogramming and refill.

1–10 of 11

1/2

HCPCS and supply codesHCPCS

A4300	Implantable access catheter, external access.
A4301	Implantable access total catheter, port/reservoir.
E0782	Infusion pump, implantable, nonprogrammable.
E0783	Infusion pump system, implantable, programmable.
E0785	Implantable intraspinal catheter used with implantable infusion pump, replacement.
E0786	Implantable programmable infusion pump, replacement.
C1772	Infusion pump, programmable (implantable).
C1755	Catheter, intraspinal.
J2274	Injection, morphine sulfate, preservative free for epidural or intrathecal use, 10 mg.
S0093	Injection, morphine sulfate, 500 mg (loading dose for infusion pump).

inv-09: Trial pain reduction threshold — threshold value (e.g. ≥ 50%).

Trial pain reduction threshold≥ 50% reduction in pain during preliminary epidural or intrathecal trial

Functional improvement requirement (nonmalignant)Trial must show ≥ 50% reduction in pain and increase in function for nonmalignant indications

Minimal side effectsTrial response must occur with minimal intolerable adverse effects

inv-10: Life expectancy threshold (malignant) — e.g. > 3 months.

Life expectancy threshold (malignant)> 3 months

Life expectancy threshold (nonmalignant)

Provider Responsibilities, Prior Authorization, and Documentation

Prior Authorization

Prior authorization required; use listed procedure and device codes

Prior authorization is required for services and device supply codes listed in this policy; those CPT and HCPCS codes must be used on authorization requests and claims submissions.

Affected CPT and HCPCS/HCPCS-like codes include (but are not limited to) 62320–62327, 62350–62371, A4300, A4301, E0782, E0783, E0785, E0786, C1772, C1755, J2274, S0093.

Note

Policy is a medical necessity guide — confirm benefit coverage

This clinical policy is intended as a guide to medical necessity to assist coverage decisions and benefit administration; it does not replace plan-level benefit verification or constitute a guarantee of payment.

Providers should confirm plan-specific prior authorization requirements and member benefit coverage in the member's coverage documents.

Required Conservative Therapies and Documentation

inv-23: Documentation of prior conservative treatments tried and failed — criteria group

Documentation must demonstrate prior conservative treatments attempted and reason(s) for failure or intolerance:

Required documentation of conservative treatments: For nonmalignant pain, documentation of failure or inability to tolerate conservative treatments including, but not limited to, systemic pharmacotherapy, physical therapy, behavioral health treatment for pain, and appropriate nonsurgical treatments. Records should document treatment type(s), duration, response, and reasons for discontinuation or intolerance.

Contextual documentation elements: Also document indication (malignant vs nonmalignant chronic intractable pain), prior attempts at medical and noninvasive care, results of preliminary intrathecal/epidural trial (including pain reduction ≥ 50% and increased function for nonmalignant pain where required), opioid wean of ≥50% prior to trial when indicated, psychological evaluation findings, and absence of listed contraindications.

Frequency Limits and Trial Requirements

inv-24: Preliminary intrathecal or epidural trial — Trial infusion prior to permanent implantation; exceptions for advanced malignant disease may be reviewed case-by-case.

Trial infusion required prior to permanent implantationA preliminary intrathecal or epidural trial infusion is required before permanent pump implantation (with or without catheter)

Exception for advanced malignant diseaseExceptions to the trial requirement for limited advanced malignant cases may be reviewed case-by-case

Trial purposeTrial determines adequate response (predefined improvement, usually ≥50%) without intolerable adverse effects

Imaging and Procedural Guidance

Billing Rule

Use fluoroscopy or CT for catheter placement/implantation

Catheter placement for trial or implantation is typically performed under fluoroscopic guidance or CT; use imaging guidance as specified by procedure coding and clinical requirements.

Several CPT codes differentiate procedures performed with or without imaging guidance (eg, 62321, 62323, 62327).
Document imaging used for catheter positioning in operative/reporting notes.

Background and Clinical Context

Implantable intrathecal and epidural drug delivery systems (also called intrathecal drug delivery or IDD systems) are devices that combine an implanted catheter with a constant-flow or programmable pump to deliver medications directly into the intrathecal or epidural space for targeted central nervous system analgesia.

These systems are used primarily for long-term management of select patients with recalcitrant pain—most commonly cancer-related pain—and are considered for severe nonmalignant pain only after conservative and surgical options have failed. A preliminary intrathecal or epidural trial infusion is performed to assess response before permanent implantation.

Successful trials are typically defined as providing a predefined improvement in pain, usually ≥ 50%, without intolerable adverse effects; if the trial is successful, the pump and catheter may be implanted under general anesthesia, with catheter positioning generally performed under fluoroscopic guidance.

Definitions

inv-20: Intrathecal drug delivery system (IDD) — Definition of implanted pump and catheter delivering drug to CSF; programmable features.

DefinitionAn implanted pump and catheter that delivers drug directly into the spinal (cerebrospinal) fluid

Programmable featuresDevice can be constant-flow or programmable for continuous or variable infusion rates

Indication contextProvides targeted CNS delivery for long-term management of select patients with intractable pain

inv-21: Successful trial — Definition: preliminary infusion providing predefined improvement in pain (usually ≥50%) without intolerable adverse effects.

Successful trial definitionA preliminary intrathecal or epidural infusion that provides a predefined improvement in pain, usually ≥50%, without intolerable adverse effects

Nonmalignant requirement

Not Covered Indications

Intrathecal or epidural pump therapy is not covered for nonmalignant pain when all specified trial and permanent-implantation criteria have not been met. This includes failure to document prior conservative treatments, absence of a successful preliminary trial (see trial response requirements), or lack of required documentation such as psychological evaluation and opioid-wean plans.

Procedures are also not covered when any listed absolute contraindication is present (for example, active systemic infection, active infection at the implantation site, active substance abuse, or known allergy to implant materials). Providers should address contraindications prior to submission to avoid denials.

Provider Coding and Billing Reminders